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LETTER
A novel phenotypic assay of hepatitis B virus polymerase with
extensive site-specific mutagenesis
Dear Editor,
A common reason for drug failure during long-term
treatment of chronic hepatitis B with nucleot(s)ide
analogues (NUCs) is the emergence of drug resistance
(Das et al. ,  2001). Most primary NUCs-resistant
mutations identified in clinical samples have been
limited to a minority of amino acids (usually less than
three kinds) that replace the wild type amino acid at a
single site (Kirishima et al., 2002). However, each site
should, theoretically, have the same opportunity to be
mutated to any of the 19 amino acids other than that of
the wild type during the DNA synthesis catalyzed by the
error-prone viral polymerase (Bartholomeusz et al.,
2004). Therefore, precisely how these undiscovered
possible mutations influence the viral phenotype is an
interesting research question. To address this issue,
Baldick et al. constructed a comprehensive panel of
clones containing every possible amino acid at the three
primary amino acid positions related to entecavir
resistance (rtT184, rtS202, or rtM250) in the lamivudine
(LAM)-resistant hepatitis B virus (HBV) background
(rtM204V + rtL180M) to determine the phenotypic
impact of these substitutions (Baldick et al., 2008).
Although extensive mutagenesis analysis is very useful,
this kind of assay is usually difficult to conduct. The
construction of mutated plasmids would be laborious if
there are a large amount of mutants need to be tested. In
addition, the transfection step can be a source of
variation, and the plasmid DNA transfected into cells, if
not completely eliminated during the purification step,
will interfere with the detection of HBV DNA replicative
intermediates. Herein, we report an alternative method
for conducting an extensive mutagenesis phenotype
assay of HBV polymerase. This method is based on our
previously developed polymerase trans-complement
strategy (Luo et al., 2016). Using the well-known LAM-
resistant mutation rtM204 site as a target, we have demon-
strated the feasibility of this method.
The alternative strategy to perform an extensive muta-
genesis phenotype assay that combines randomized
mutagenesis and HBV polymerase trans-complementa-
tion is outlined in Figure 1A. The reverse primer Rpol204
(Supplementary Table 1), which has two randomized
nucleotides (NNT) at the second and third sites of the
rt204 codon (ATG), was used to amplify a fragment to-
gether with a forward primer targeting the backbone of
the plasmid pLentipol-D. The fragment was inserted at
the corresponding region on pLentipol-D by fragment-
substitution reaction (FSR) (Hu et al., 2012), generating
plasmids carrying NN mutations at the rt204 codon.
Plasmids carrying different mutations were pooled and
used to package the lentiviruses. After the transduction
of the lentiviruses carrying the blasticidin-resistant gene
into the cell line 293HBV-pol-, monoclonal cells were
selected with antibiotics. The genomic DNA samples
from these clones were amplified with a pair of primers
(the forward primer anneals to a region upstream of
rt204M, and the reverse primer anneals to a sequence on
the lentiviral vector) and sequenced to identify the muta-
tions of rt204 in each clone. Finally, expanded mono-
clonal cells were used to test the replication capability of
the HBV DNA and the LAM susceptibility by real-time
PCR.
To generate randomized mutations at rtM204 on the
lentipol plasmids, a primer (Rpol204) containing degen-
erate bases was used to perform FSR. In brief, a DNA
fragment was amplified with the primers lenti6744F and
Rpol204 (Supplementary Table 1) using pLentipol-D as
a template. The plasmid pLentipol-D was constructed
previously (Luo et al., 2016), which expresses an HBV
(genotype D) polymerase gene. This gel-purified frag-
ment (about 4.5 kb) was used as a mega-primer to substi-
tute the corresponding region on pLentipol-D. After Dpn
I digestion, the FSR product was transformed into com-
petent DH5ɑ cells. Clones containing different muta-
tions at rtM204 were characterized by sequencing. Among
the 50 clones selected for sequencing, 30 contained a
qualified sequence. All 16 possible types of theoretical
mutations were identified, except for the mutation of
ACG (Supplementary Table S2). The absence of an
ACG mutant might be attributed to the paucity of this
form in the primer mix, or to the fact that the quantity of
clones picked was not sufficient. Of the identified muta-
tion forms, clone numbers varied from 1 to 5. Since ACG
encodes threonine as do ACU, ACA, and ACC, we did
not further pursue this mutant.
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Liu, Y., Luo, Y. Y., Cai, X. F., Long, Q. X., Gan, C. Y., Yang, L. Q., ... & Hu, J. L. (2017). A novel phenotypic assay of hepatitis B virus 
polymerase with extensive site-specific mutagenesis. Virologica Sinica, 2(32), 167-170. https://doi.org/10.1007/s12250-016-3932-0
The bacteria containing the 15 kinds of plasmids were
respectively mixed and cultured for plasmid preparation.
The plasmid mixture was then used to package the len-
tiviruses. The lentiviruses were transduced into the
293HBV-pol- cell line, which is a modified HEK293 cell
line stably expressing all HBV replication-related ele-
ments except for the polymerase (Luo et al., 2016).
Blasticidin-resistant monoclones were selected by lim-
ited titration. To characterize the mutations integrated into
these cells, the fragments were amplified from the chro-
mosome DNA of these cells with the primers F260 and
RlentiPCR (Supplementary Table S1). Because one of
the two primers targets the sequence on the lentiviral
vector backbone, the preexisting integrated copy of HBV
DNA in 293HBV-pol- cells would not be amplified. Thirty-
seven of the 40 clones assayed contained the polymerase
gene. The number of clones with different mutation
forms varied from 0 to 7 (Table 1). Three mutation forms
(ACA, AGC, and AGT) were not found, and thus the
M204S mutant was missing. This is possibly due to low
titers of corresponding lentiviruses with rt204S in the
lentivirus pool, or because these two lentiviruses were
not packaged successfully.
The replication capability of each of the polymerase
variants was assayed under 0 μmol/L or 20 μmol/L of
LAM using the stable cell lines obtained. The replica-
tion capability under 0 μmol/L LAM can reflect the “na-
tural” activity, while that under 20 μmol/L of LAM re-
flects the "fitness" under drug pressure. Intracellular nuc-
leocapsid-associated HBV DNA levels were measured
by real-time PCR, and mitochondria DNA was used as
reference (Seeger and Sohn, 2014). The F1927 and
R2051 primers were used in real-time PCR (Supplement-
ary Table S1), and the reaction system contained 10 μL
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FastStart Universal SYBR Green Master (Roche Diag-
nostics, Mannheim, Germany), 2 μL of DNA, 0.1 μL (10
μmol/L) of each primer, and 7.8 μL of H2O. The ampli-
fication conditions were as follows: denaturation at 95 °C
for 10 min, followed by 35 cycles of denaturation at 94 °C
for 15 s, annealing at 60 °C for 15 s, and extension at 72 °C
for 20 s.
Without LAM in the medium, the wild-type poly-
merase (rt204M) replicated at the highest level (Figure
1B). The rt204I mutant showed 3.039% of the replicat-
ing capacity of the wild type, which was similar to that
of the rt204N or rt204K mutant. However, the rt204T
and rt204R mutants presented much lower replication ca-
pacities (0.102% and 0.005%, respectively), indicating a
severe negative impact of these mutations on the func-
tion of polymerase. The functional deficiency of these
mutants is consistent with the pivotal role of the YMDD
motif in the activity of polymerase, and explains why
these mutations are seldom found in clinical samples
(Chayama et al., 1998). Ono-Nita et al. (1999) also reported
that the rtM204T, rtM204R, and rtM204K mutants were
incompetent for virus replication during transient trans-
fection in vitro.
In the presence of 20 μmol/L LAM, the replication
level of the wild-type polymerase was reduced by 6.842 ±
0.983-fold, whereas the polymerases of the rt204I and
rt204T mutants remained essentially unchanged (1.201 ±
0.031- and 1.174 ± 0.146-fold reductions, respectively),
compared to the observed levels without LAM treatment
(Figure 1C). The polymerase of rt204N replicated HBV
DNA with a dramatically decreased efficiency (10.723 ±
0.653-fold), indicating a higher sensitivity to LAM, even
compared to that of the wild type. The rt204K and
rt204R mutants showed moderate sensitivities to LAM,
with fold changes of 2.503 ± 0.295 and 2.831 ± 0.225,
respectively. All of these mutants showed higher sensi-
tivities than the rt204I mutant, indicating reduced 'fit-
ness' under LAM treatment, which is concordant with the
fact that the rt204I variant is predominantly selected over
other mutants in patients treated with LAM.
In summary, we developed a novel mutagenesis phe-
notypic assay with the following characteristics: (1) ac-
quisition of extensive site-specific mutations through a
PCR step and FSR; (2) production of a lentivirus pool
expressing different polymerase mutants via one-time
lentivirus packaging; (3) generation of stable cell lines
that replicate HBV DNA by integrated polymerase
mutants, which can help to establish an experimental
system with lower variation and higher convenience.
This randomized phenotypic assay of HBV polymerase
provides a useful tool for assessing the replication fit-
ness and drug susceptibility of HBV variants and quasi-
species, which may offer new insight for the NUC ther-
apy and the prognosis of patients with chronic hepati-
tis B.
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Table 1.  Characterization of monoclonal cells
Nucleotides (ANN) Amino acid Number of clones
AUG* M204 WT 3
AUA* M204I 4
AUU 1
AUC 2
ACA M204T 0
ACU 2
ACC* 7
AAA M204K 5
AAG* 2
AAU* M204N 3
AAC 4
AGA M204R 3
AGG* 1
AGC M204S 0
AGU 0
37
Note: The genomic DNAs were purified from 40 clones, 37
of  which  were  found  to  have  the  integrated  polymerase
gene. The number of different mutants is listed. * Cell lines
with these mutants were subjected to the phenotype assay.
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Table S1.  Primer sequences
Primer 5′–3′
lenti6744F AGGTTTCCCGACTGGAAAGC
Rpol204 TTGGCCCCCAATACCACATCATCNNTATAACTGAAAGCCAAACAGTGGG GGA
F260 TAGACTCGTGGTGGACTTCTCT
RlentiPCR GAATCGAGACCGAGG AGAGGGT
F1927 GGAGCTACTGTGGAGTTACTCT
R2051 TTGCCTGAGTGCAGTATGGTGA
Table S2.  Distribution of mutations among the 30 plasmids
sequenced
Nucleotides (ANN) Amino acid Number of clones
AUG M204 WT 3
AUA M204I 1
AUU M204I 1
AUC M204I 2
ACA M204T 5
ACU M204T 1
ACC M204T 2
ACG M204T 0
AAA M204K 3
AAG M204K 1
AAU M204N 1
AAC M204N 2
AGA M204R 4
AGG M204R 1
AGC M204S 2
AGU M204S 1
Total 30
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